Cargando…

KRAS mutant colorectal tumors: Past and present

The treatment of metastatic colorectal cancer (mCRC) remains one of the largest hurdles in cancer therapeutics to date. The most advanced treatment option for mCRC patients are anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) that bind to and inhibit the activity of EGFR. Wh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brand, Toni M., Wheeler, Deric L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2012
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3398915/ https://www.ncbi.nlm.nih.gov/pubmed/22714415 http://dx.doi.org/10.4161/sgtp.18751

Ejemplares similares

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
por: Dunn, Emily F., et al.
Publicado: (2010)

Defeat mutant KRAS with synthetic lethality
por: Pang, Xiufeng, et al.
Publicado: (2016)

Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future
por: Uras, Iris Z., et al.
Publicado: (2020)

Distinct metabolic preference of atypical KRAS mutant
por: Cheong, Heesun
Publicado: (2020)

Pidotimod: the past and the present
por: Zuccotti, Gian Vincenzo, et al.
Publicado: (2013)

Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer
por: Kitai, Hidenori, et al.
Publicado: (2016)

Vaccine equity: Past, present, and future
por: van der Graaf, Rieke, et al.
Publicado: (2022)

Mutant KRAS triggers functional reprogramming of tumor-associated macrophages in colorectal cancer
por: Liu, Huashan, et al.
Publicado: (2021)

Anti-obesity drugs: past, present and future
por: Rodgers, R. John, et al.
Publicado: (2012)

Mesenchymal Stem Cells: The Past, the Present, the Future
por: Caplan, Arnold I.
Publicado: (2010)

The past, present and future of protein-based materials
por: Abascal, Nadia C., et al.
Publicado: (2018)

Opinion: regulatory genotoxicity: past, present and future
por: Hayashi, Makoto
Publicado: (2022)

Divide and conquer: towards isoform-specific diagnosis and therapy of KRAS-mutant lung cancer
por: Allemann, Anna T., et al.
Publicado: (2023)

Community Pharmacy Practice in India: Past, Present and Future
por: Basak, Subal Chandra, et al.
Publicado: (2009)

Vascular AGE-ing by methylglyoxal: the past, the present and the future
por: Schalkwijk, Casper G.
Publicado: (2015)

Past, Present, and Future of Minimally Invasive Abdominal Surgery
por: Antoniou, Stavros A., et al.
Publicado: (2015)

KRAS: Druggable at Last
por: Herzberg, Benjamin O, et al.
Publicado: (2023)

Bariatric/Metabolic Surgery for Diabetes: Lessons From the Past and Present
por: Purnell, Jonathan Q., et al.
Publicado: (2019)

Integrated multi-omics characterization of KRAS mutant colorectal cancer
por: Chong, Wei, et al.
Publicado: (2022)

Methodological developments in searching for studies for systematic reviews: past, present and future?
por: Lefebvre, Carol, et al.
Publicado: (2013)

The KRAS-Mutant Consensus Molecular Subtype 3 Reveals an Immunosuppressive Tumor Microenvironment in Colorectal Cancer
por: Tanjak, Pariyada, et al.
Publicado: (2023)

Three stories about the conduct of science: Past, future, and present
por: Neylon, Cameron
Publicado: (2011)

Quantifying β-Cells in Health and Disease: The Past, the Present, and the Need
por: Kahn, Steven E.
Publicado: (2013)

Newborn Screening for X-Linked Adrenoleukodystrophy: Past, Present, and Future
por: Moser, Ann B., et al.
Publicado: (2022)

KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges
por: Ceddia, Serena, et al.
Publicado: (2022)

Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors
por: Dias Carvalho, Patrícia, et al.
Publicado: (2019)

The opioid crisis: past, present and future policy climate in Ontario, Canada
por: Morin, Kristen A., et al.
Publicado: (2017)

KRAS inhibitors: going noncovalent
por: Drosten, Matthias, et al.
Publicado: (2022)

Detection of Mutant RAS Subpopulations in Colorectal Cancer Patients
por: Banda, Malathi
Publicado: (2015)

Yes and Lyn play a role in nuclear translocation of the Epidermal Growth Factor Receptor
por: Iida, Mari, et al.
Publicado: (2012)

Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer
por: Knickelbein, Kyle, et al.
Publicado: (2014)

Bromelain effectively suppresses Kras-mutant colorectal cancer by stimulating ferroptosis
por: Park, Sujeong, et al.
Publicado: (2018)

Dual inhibition of VEGF and PARP suppresses KRAS-mutant colorectal cancer
por: Zhong, Longhui, et al.
Publicado: (2020)

Targeting Myc-driven stress vulnerability in mutant KRAS colorectal cancer
por: Ruan, Hang, et al.
Publicado: (2022)

The past, present and future of the International Journal of Behavioral Nutrition and Physical Activity
por: Brug, Johannes, et al.
Publicado: (2006)

The Path to Eliminating Cervical Cancer in Canada: Past, Present and Future Directions
por: Caird, Hannah, et al.
Publicado: (2022)

A Decade of GigaScience: Women in Science: Past, Present, and Future
por: Liu, Lijun, et al.
Publicado: (2022)

The Specific Gravity-Free Method for the Isolation of Circulating Tumor KRAS Mutant DNA and Exosome in Colorectal Cancer
por: Lee, Tae Hee, et al.
Publicado: (2021)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2bl80b0achru1hgnd8m3v5268b